Christos Reppas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5725790/publications.pdf

Version: 2024-02-01

148 papers	9,976 citations	50566 48 h-index	42259 96 g-index
153 all docs	153 docs citations	153 times ranked	5474 citing authors

#	Article	IF	Citations
1	UNGAP best practice for improving solubility data quality of orally administered drugs. European Journal of Pharmaceutical Sciences, 2022, 168, 106043.	1.9	9
2	In Vitro Simulation of the Environment in the Upper Gastrointestinal Lumen After Drug Administration in the Fed State Using the TIM-1 System and Comparison With Luminal Data in Adults. Journal of Pharmaceutical Sciences, 2022, 111, 197-205.	1.6	4
3	On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state. European Journal of Pharmaceutical Sciences, 2022, 168, 106034.	1.9	9
4	On the usefulness of four in vitro methodologies in screening for product related differences in tacrolimus exposure after oral administration of amorphous solid dispersions with modified release characteristics in the fasted state. Journal of Drug Delivery Science and Technology, 2022, 69, 102990.	1.4	1
5	Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective. European Journal of Pharmaceutical Sciences, 2022, 172, 106100.	1.9	12
6	Usefulness of Optimized Human Fecal Material in Simulating the Bacterial Degradation of Sulindac and Sulfinpyrazone in the Lower Intestine. Molecular Pharmaceutics, 2022, 19, 2542-2548.	2.3	3
7	Characteristics of Contents of Lower intestine in the 65â€“74ÂYears of Age Range Could Impact the Performance of Safe and Efficacious Modified Release Products. Journal of Pharmaceutical Sciences, 2021, 110, 251-258.	1.6	9
8	Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration. Journal of Pharmacy and Pharmacology, 2021, 73, 437-446.	1.2	8
9	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Advanced Drug Delivery Reviews, 2021, 171, 289-331.	6.6	84
10	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 2021, 162, 105812.	1.9	137
11	Jennifer Dressman - 40 years of oral drug absorption. Journal of Pharmaceutical Sciences, 2021, , .	1.6	0
12	The mechanism of solifenacin release from a pH-responsive ion-complex oral suspension in the fasted upper gastrointestinal lumen. European Journal of Pharmaceutical Sciences, 2020, 142, 105107.	1.9	8
13	On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food. AAPS Journal, 2020, 22, 6.	2.2	11
14	Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions. AAPS Journal, 2020, 22, 126.	2.2	9
15	Dissolution testing of modified release products with biorelevant media: An OrBiTo ring study using the USP apparatus III and IV. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 40-49.	2.0	5
16	Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous Suspension. AAPS Journal, 2020, 22, 146.	2.2	6
17	Novel Biphasic Lipolysis Method To Predict in Vivo Performance of Lipid-Based Formulations. Molecular Pharmaceutics, 2020, 17, 3342-3352.	2.3	18
18	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. European Journal of Pharmaceutical Sciences, 2020, 155, 105517.	1.9	18

#	Article	IF	Citations
19	Characteristics of contents in the upper gastrointestinal lumen after a standard high-calorie high-fat meal and implications for the in vitro drug product performance testing conditions. European Journal of Pharmaceutical Sciences, 2020, 155, 105535.	1.9	18
20	On the Usefulness of Two Small-Scale In Vitro Setups in the Evaluation of Luminal Precipitation of Lipophilic Weak Bases in Early Formulation Development. Pharmaceutics, 2020, 12, 272.	2.0	18
21	Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapadâ“‡ membrane and in vivo absorption. European Journal of Pharmaceutical Sciences, 2020, 152, 105452.	1.9	17
22	Measuring pH and Buffer Capacity in Fluids Aspirated from the Fasted Upper Gastrointestinal Tract of Healthy Adults. Pharmaceutical Research, 2020, 37, 42.	1.7	20
23	On the usefulness of compendial setups and tiny-TIM system in evaluating the in vivo performance of oral drug products with various release profiles in the fasted state: Case example sodium salt of A6197. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 154-162.	2.0	13
24	Disposition of two highly permeable drugs in the upper gastrointestinal lumen of healthy adults after a standard high-calorie, high-fat meal. European Journal of Pharmaceutical Sciences, 2020, 149, 105351.	1.9	13
25	The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation.. European Journal of Pharmaceutical Sciences, 2020, 151, 105377.	1.9	14
26	Workshop Report: USP Workshop on Advancements in In Vitro Performance Testing of Drug Products. Dissolution Technologies, 2020, 27, 52-70.	0.2	2
27	Exploring the impact of Crohnâ€™s disease on the intragastric environment of fasted adults. ADMET and DMPK, 2020, 8, 122.	1.1	4
28	Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products â€“ a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 603-642.	1.2	29
29	In vitro methods to assess drug precipitation in the fasted small intestine â€“ a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 536-556.	1.2	39
30	Biphasic drug release testing coupled with diffusing wave spectroscopy for mechanistic understanding of solid dispersion performance. European Journal of Pharmaceutical Sciences, 2019, 137, 105001.	1.9	18
31	Formulation, characterization and antimicrobial activity of tablets of essential oil prepared by compression of spray-dried powder. Journal of Drug Delivery Science and Technology, 2019, 50, 226-236.	1.4	20
32	Toward the establishment of a standardized pre-clinical porcine model to predict food effects â€“ Case studies on fenofibrate and paracetamol. International Journal of Pharmaceutics: X, 2019, 1, 100017.	1.2	3
33	The mechanisms of pharmacokinetic food-drug interactions â€“ A perspective from the UNGAP group. European Journal of Pharmaceutical Sciences, 2019, 134, 31-59.	1.9	224
34	Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. European Journal of Pharmaceutical Sciences, 2019, 134, 153-175.	1.9	146
35	5. Estimation of intraluminal drug solubility. , 2019, , 133-148.		1
36	A Novel Rheological Method to Assess Drug-Polymer Interactions Regarding Miscibility and Crystallization of Drug in Amorphous Solid Dispersions for Oral Drug Delivery. Pharmaceutics, 2019, 11, 625.	2.0	6

#	Article	IF	Citations
37	In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 70-83.	2.0	91
38	The impact of food intake on the luminal environment and performance of oral drug products with a view toin vitroandin silicosimulations: a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 557-580.	1.2	51
39	Workshop Report: USP Workshop on Exploring the Science of Drug Absorption. Dissolution Technologies, 2019, 26, 38-66.	0.2	1
40	Evaluating the clinical importance of bacterial degradation of therapeutic agents in the lower intestine of adults using adult fecal material. European Journal of Pharmaceutical Sciences, 2018, 125, 142-150.	1.9	14
41	FIP Guidelines for Dissolution Testing of Solid Oral Products. Journal of Pharmaceutical Sciences, 2018, 107, 2995-3002.	1.6	12
42	The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration. AAPS Journal, 2018, 20, 71.	2.2	30
43	Physiologically Based Absorption Modeling of Salts of Weak Bases Based on Data in Hypochlorhydric and Achlorhydric Biorelevant Media. AAPS PharmSciTech, 2018, 19, 2851-2858.	1.5	21
44	Mapping the intermediate digestion phases of human healthy intestinal contents from distal ileum and caecum at fasted and fed state conditions. Journal of Pharmacy and Pharmacology, 2017, 69, 265-273.	1.2	5
45	The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: Data in biorelevant media and in human aspirates. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 115, 94-101.	2.0	19
46	Mechanistic investigation of the negative food effect of modified release zolpidem. European Journal of Pharmaceutical Sciences, 2017, 102, 284-298.	1.9	57
47	Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs. Molecular Pharmaceutics, 2017, 14, 4181-4191.	2.3	26
48	Ex vivo evaluation of degradation rates of metronidazole and olsalazine in distal ileum and in cecum: The impact of prandial state. International Journal of Pharmaceutics, 2017, 534, 237-241.	2.6	11
49	Evaluation of the Impact of Excipients and an Albendazole Salt on Albendazole Concentrations in Upper Small Intestine Using an InÂVitro Biorelevant Gastrointestinal Transfer (BioGIT) System. Journal of Pharmaceutical Sciences, 2016, 105, 2896-2903.	1.6	26
50	Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug â€“ Drug Interaction Studies. Pharmaceutical Research, 2016, 33, 1399-1412.	1.7	64
51	The Impact of Handling and Storage of Human Fecal Material on Bacterial Activity. Journal of Pharmaceutical Sciences, 2016, 105, 3458-3461.	1.6	6
52	In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT. International Journal of Pharmaceutics, 2016, 515, 352-358.	2.6	29
53	Effectiveness of supersaturation promoting excipients on albendazole concentrations in upper gastrointestinal lumen of fasted healthy adults. European Journal of Pharmaceutical Sciences, 2016, 91, 11-19.	1.9	19
54	An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation. European Journal of Pharmaceutical Sciences, 2016, 82, 106-114.	1.9	60

#	Article	IF	Citations
55	In-vitro evaluation of performance of solid immediate release dosage forms of weak bases in upper gastrointestinal lumen: experience with miconazole and clopidogrel salts. Journal of Pharmacy and Pharmacology, 2016, 68, 579-587.	1.2	8
56	Characterization of Contents of Distal Ileum and Cecum to Which Drugs/Drug Products are Exposed During Bioavailability/Bioequivalence Studies in Healthy Adults. Pharmaceutical Research, 2015, 32, 3338-3349.	1.7	59
57	Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin. International Journal of Pharmaceutics, 2015, 490, 368-374.	2.6	10
58	Two-Stage Single-Compartment Models to Evaluate Dissolution in the Lower Intestine. Journal of Pharmaceutical Sciences, 2015, 104, 2986-2997.	1.6	15
59	Structural features of colloidal species in the human fasted upper small intestine. Journal of Pharmacy and Pharmacology, 2015, 67, 486-492.	1.2	17
60	In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 173-182.	2.0	152
61	In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 39-50.	2.0	39
62	Identification of key factors affecting the oral absorption of salts of lipophilic weak acids: a case example. Journal of Pharmacy and Pharmacology, 2014, 67, 56-67.	1.2	24
63	In vivo methods for drug absorption â€“ Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences, 2014, 57, 99-151.	1.9	226
64	Biorelevant media for transport experiments in the Caco-2 model to evaluate drug absorption in the fasted and the fed state and their usefulness. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 438-448.	2.0	41
65	Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools. European Journal of Pharmaceutical Sciences, 2014, 63, 233-242.	1.9	63
66	Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: Case studies with fenofibrate. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 427-437.	2.0	111
67	Oral biopharmaceutics tools â€“ Time for a new initiative â€“ An introduction to the IMI project OrBiTo. European Journal of Pharmaceutical Sciences, 2014, 57, 292-299.	1.9	91
68	Increasing the biorelevance of simulated intestinal fluids for better predictions of drug equilibrium solubility in the fasted upper small intestine. ADMET and DMPK, 2014, 2, .	1.1	5
69	In Vitro and Ex Vivo Investigation of the Impact of Luminal Lipid Phases on Passive Permeability of Lipophilic Small Molecules Using PAMPA. Pharmaceutical Research, 2013, 30, 3145-3153.	1.7	12
70	Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 633-641.	2.0	53
71	Unravelling the ultrastructure of ascending colon fluids from patients with ulcerative colitis by cryogenic transmission electron microscopy. Journal of Pharmacy and Pharmacology, 2013, 65, 1482-1487.	1.2	9
72	AAPS Workshop Report on Biorelevant In Vitro Performance Testing of Orally Administered Dosage Forms. Dissolution Technologies, 2013, 20, 45-49.	0.2	1

#	Article	IF	Citations
73	Insights into Intermediate Phases of Human Intestinal Fluids Visualized by Atomic Force Microscopy and Cryo-Transmission Electron Microscopy ex Vivo. Molecular Pharmaceutics, 2012, 9, 237-247.	2.3	59
74	In vitro vs. canine data for assessing early exposure of doxazosin base and its mesylate salt. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 402-409.	2.0	24
75	An In Vitro Methodology for Forecasting Luminal Concentrations and Precipitation of Highly Permeable Lipophilic Weak Bases in the Fasted Upper Small Intestine. Pharmaceutical Research, 2012, 29, 3486-3498.	1.7	79
76	Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers. Molecular Pharmaceutics, 2012, 9, 1189-1198.	2.3	60
77	Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 127-138.	2.0	69
78	Biorelevant in-vitro performance testing of orally administered dosage forms. Journal of Pharmacy and Pharmacology, 2012, 64, 919-930.	1.2	46
79	Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 257-264.	2.0	93
80	Precipitation in and Supersaturation of Contents of the Upper Small Intestine After Administration of Two Weak Bases to Fasted Adults. Pharmaceutical Research, 2011, 28, 3145-3158.	1.7	179
81	Degradation kinetics of metronidazole and olsalazine by bacteria in ascending colon and in feces of healthy adults. International Journal of Pharmaceutics, 2011, 413, 81-86.	2.6	40
82	Unusual solubility behaviour of cyclosporin A in aqueous media. Journal of Pharmacy and Pharmacology, 2011, 43, 287-289.	1.2	108
83	Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspectsâ€. Journal of Pharmacy and Pharmacology, 2010, 56, 453-462.	1.2	206
84	Media to simulate the postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts. Journal of Pharmacy and Pharmacology, 2010, 56, 605-610.	1.2	104
85	Plasma profiles of lycopene after single oral and intravenous administrations in dogs. Journal of Pharmacy and Pharmacology, 2010, 58, 1211-1217.	1.2	10
86	Stability of oleuropein in the human proximal gut. Journal of Pharmacy and Pharmacology, 2010, 61, 143-149.	1.2	25
87	Characterization of the Ascending Colon Fluids in Ulcerative Colitis. Pharmaceutical Research, 2010, 27, 1620-1626.	1.7	30
88	Biorelevant Media to Simulate Fluids in the Ascending Colon of Humans and Their Usefulness in Predicting Intracolonic Drug Solubility. Pharmaceutical Research, 2010, 27, 2187-2196.	1.7	95
89	A LC-MS-MS Method for Determination of Low Doxazosin Concentrations in Plasma after Oral Administration to Dogs. Journal of Chromatographic Science, 2010, 48, 114-119.	0.7	15
90	Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. Journal of Pharmacy and Pharmacology, 2010, 58, 827-836.	1.2	16

#	Article	IF	Citations
91	Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 95-104.	2.0	119
92	Simulation of gastric lipolysis and prediction of felodipine release from a matrix tablet in the fed stomach. European Journal of Pharmaceutical Sciences, 2009, 37, 133-140.	1.9	38
93	Postprandial Evolution in Composition and Characteristics of Human Duodenal Fluids in Different Nutritional States. Journal of Pharmaceutical Sciences, 2009, 98, 1177-1192.	1.6	112
94	Estimation of intragastric drug solubility in the fed state: comparison of various media with data in aspirates. Biopharmaceutics and Drug Disposition, 2009, 30, 318-325.	1.1	43
95	Postprandial Changes in Solubilizing Capacity of Human Intestinal Fluids for BCS Class II Drugs. Pharmaceutical Research, 2009, 26, 1456-1466.	1.7	109
96	Characterization of the Contents of Ascending Colon to Which Drugs are Exposed After Oral Administration to Healthy Adults. Pharmaceutical Research, 2009, 26, 2141-2151.	1.7	118
97	Hydroxypropylmethylcellulose significantly lowers blood cholesterol in mildly hypercholesterolemic human subjects. European Journal of Clinical Nutrition, 2009, 63, 71-77.	1.3	35
98	A comparative study of different release apparatus in generating in vitroâ€“in vivo correlations for extended release formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 115-120.	2.0	59
99	Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 107-114.	2.0	144
100	Stability of oleuropein in the human proximal gut. Journal of Pharmacy and Pharmacology, 2009, 61, 143-149.	1.2	4
101	Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update. Pharmaceutical Research, 2008, 25, 1663-1676.	1.7	633
102	In vitro methods can forecast the effects of intragastric residence on dosage form performance. European Journal of Pharmaceutical Sciences, 2008, 33, 445-451.	1.9	20
103	Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 338-345.	2.0	24
104	Determination of intralumenal individual bile acids by HPLC with charged aerosol detection. Journal of Lipid Research, 2008, 49, 2690-2695.	2.0	39
105	1H NMR Monitoring of the Canine Metabolic Profile after Oral Administration of Xenobiotics Using Multivariate Statistics. Molecular Pharmaceutics, 2007, 4, 258-268.	2.3	3
106	Estimating drug solubility in the gastrointestinal tract. Advanced Drug Delivery Reviews, 2007, 59, 591-602.	6.6	199
107	Estimation of Intragastric Solubility of Drugs: In What Medium?. Pharmaceutical Research, 2007, 24, 909-917.	1.7	88
108	Solubilization and quantification of lycopene in aqueous media in the form of cyclodextrin binary systems. International Journal of Pharmaceutics, 2006, 309, 115-122.	2.6	40

#	Article	IF	Citations
109	Optimization and validation of a high-performance liquid chromatographic method with UV detection for the determination of ketoconazole in canine plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 839, 62-67.	1.2	28
110	Characterization of the Human Upper Gastrointestinal Contents Under Conditions Simulating Bioavailability/Bioequivalence Studies. Pharmaceutical Research, 2006, 23, 165-176.	1.7	558
111	Canine Intestinal Contents vs. Simulated Media for the Assessment of Solubility of Two Weak Bases in the Human Small Intestinal Contents. Pharmaceutical Research, 2006, 23, 1373-1381.	1.7	141
112	Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). Journal of Pharmaceutical Sciences, 2006, 95, 4-14.	1.6	134
113	Optimized determination of lycopene in canine plasma using reversed-phase high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 819, 149-154.	1.2	12
114	The delayed dissolution of paracetamol products in the canine fed stomach can be predicted in vitro but it does not affect the onset of plasma levels. International Journal of Pharmaceutics, 2005, 296, 87-93.	2.6	28
115	In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. European Journal of Pharmaceutical Sciences, 2005, 24, 115-122.	1.9	53
116	Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration. European Journal of Pharmaceutical Sciences, 2005, 26, 324-333.	1.9	48
117	Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 413-417.	2.0	327
118	Orally Administered Drug Products. , 2005, , 229-249.		2
119	The Flow Through Cell Methodology in the Evaluation of Intralumenal Drug Release Characteristics. Dissolution Technologies, 2005, 12, 17-21.	0.2	27
120	Comparison of simulated cumulative drug versus time data sets with indices. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56, 421-428.	2.0	21
121	Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharmaceutical Research, 2001, 18, 380-388.	1.7	188
122	In vitroâ€“in vivo correlations for lipophilic, poorly water-soluble drugs. European Journal of Pharmaceutical Sciences, 2000, 11, S73-S80.	1.9	483
123	Biorelevant Dissolution Tests with the Flow-Through Apparatus?. Dissolution Technologies, 2000, 7, 8-11.	0.2	11
124	Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharmaceutical Research, 1999, 16, 1876-1882.	1.7	143
125	Longitudinal versus radial effects of hydroxypropylmethylcellulose on gastrointestinal glucose absorption in dogs. European Journal of Pharmaceutical Sciences, 1999, 8, 211-219.	1.9	13
126	Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharmaceutical Research, 1998, 15, 698-705.	1.7	796

#	Article	IF	Citations
127	Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharmaceutical Research, 1998, 15, 11-22.	1.7	893
128	Effect of elevated viscosity in the upper gastrointestinal tract on drug absorption in dogs. European Journal of Pharmaceutical Sciences, 1998, 6, 131-139.	1.9	52
129	Ability of two comestible formulations of hydroxypropylmethylcellulose to lower serum cholesterol concentrations. European Journal of Pharmaceutical Sciences, 1996, 4, 239-245.	1.9	13
130	An improved intercept method for the assessment of absorption rate in bioequivalence studies. Pharmaceutical Research, 1996, 13, 1755-1758.	1.7	22
131	The cutoff time point of the partial area method for assessment of rate of absorption in bioequivalence studies. Pharmaceutical Research, 1994, 11, 831-834.	1.7	26
132	Enhancement of cyclosporin A solubility by d-alphatocopheryl-polyethylene-glycol-1000 succinate (TPGS). European Journal of Pharmaceutical Sciences, 1994, 1, 269-271.	1.9	25
133	Estimation of Absorption Rate Constant in a One-Compartment Model with the Profile of the Bioavailable Dose Eliminated as a Function of Multiples of Half-Life. Journal of Pharmaceutical Sciences, 1993, 82, 1298-1300.	1.6	5
134	High viscosity hydroxypropylmethylcellulose reduces postprandial blood glucose concentrations in NIDDM patients. Diabetes Research and Clinical Practice, 1993, 22, 61-69.	1.1	24
135	Viscosity modulates blood glucose response to nutrient solutions in dogs. Diabetes Research and Clinical Practice, 1992, 17, 81-88.	1.1	26
136	Equations for the fraction of bioavailable dose remaining in the body in the one-compartment model. Biopharmaceutics and Drug Disposition, 1992, 13, 229-232.	1.1	1
137	Fraction of the Bioavailable Dose Remaining in the Body at the Time of Peak Plasma Concentration in a Linear, Open, One-Compartment Model. Journal of Pharmaceutical Sciences, 1992, 81, 110-112.	1.6	3
138	On the Assessment of the Relative Magnitude of Rate Constants in the Linear Open One-Compartment Model. Journal of Pharmaceutical Sciences, 1992, 81, 1231-1233.	1.6	5
139	Effect of Hydroxypropylmethylcellulose on Gastrointestinal Transit and Luminal Viscosity in Dogs. Gastroenterology, 1991, 100, 1217-1223.	0.6	57
140	Binding of drugs in milk: the role of casein in milk protein binding--comments on the paper by Stebler and Guentert. Pharmaceutical Research, 1991, 08, 550-550.	1.7	0
141	Bioavailability study of a freeze-dried sodium phenytoin-milk formulation. Biopharmaceutics and Drug Disposition, 1991, 12, 687-695.	1.1	16
142	Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs. Gastroenterology, 1991, 100, 1217-1223.	0.6	17
143	Estimate of volume/flow ratio of gastrointestinal (GI) fluids in humans using pharmacokinetic data. Pharmaceutical Research, 1990, 07, 518-522.	1.7	8
144	Nutrient effects on intestinal drug absorption. Journal of Controlled Release, 1990, 11, 41-49.	4.8	16

#	Article	IF	Citations
145	Dissolution and in vitro permeation behaviours of dicumarol nitrofurantoin and sulfamethizole in the presence of protein. International Journal of Pharmaceutics, 1987, 37, 103-112.	2.6	9
146	Studies on Drugâ€"Milk Freeze-Dried Formulations I: Bioavailability of Sulfamethizole and Dicumarol Formulations. Journal of Pharmaceutical Sciences, 1986, 75, 692-696.	1.6	41
147	Studies on Freeze-Dried Drug-Milk Formulations II: Effect of Regenerated Fluid Volume on Nitrofurantoin Bioavailability. Journal of Pharmaceutical Sciences, 1986, 75, 1145-1150.	1.6	23
148	Application of automated flow injection analysis (FIA) to dissolution studies. International Journal of Pharmaceutics, 1984, 20, 325-333.	2.6	15